ADC Therapeutics SA Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
ADC Therapeutics SA (ADCT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 294.95 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-13
- ADC Therapeutics SA share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 110.50K shares, a 57.07% decline year-over-year.
- ADC Therapeutics SA share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 184.45K shares, a 190.07% increase year-over-year.
- ADC Therapeutics SA share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 225.74K shares, a 137.02% increase year-over-year.
- ADC Therapeutics SA share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 101.80K shares, a 17.49% increase year-over-year.
- ADC Therapeutics SA share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 648.51K shares, a 6.30% increase from fiscal 2024.
- ADC Therapeutics SA share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 610.08K shares, a 63.44% decline from fiscal 2023.
- ADC Therapeutics SA share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 1.67M shares, a 22.87% increase from fiscal 2022.
- ADC Therapeutics SA share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 1.36M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 110.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 294.95K shares 10-Q · filed 2026-08-13 | 520.69K shares derived: sum of 3 quarters · filed 2026-08-13 | 622.49K shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 184.45K shares 10-Q · filed 2026-05-04 | 410.19K shares derived: sum of 2 quarters · filed 2026-05-04 | 511.99K shares derived: sum of 3 quarters · filed 2026-05-04 | 769.37K shares derived: sum of 4 quarters · filed 2026-05-04 |
| 2025-12-31 | 225.74K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | 327.54K shares derived: sum of 2 quarters · filed 2026-03-10 | 584.92K shares derived: sum of 3 quarters · filed 2026-03-10 | 648.51K shares 10-K · filed 2026-03-10 |
| 2025-09-30 | 101.80K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | 359.19K shares derived: sum of 2 quarters · filed 2025-11-10 | 422.77K shares 10-Q · filed 2025-11-10 | 518.01K shares derived: sum of 4 quarters · filed 2025-11-10 |
| 2025-06-30 | 257.38K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 320.97K shares 10-Q · filed 2025-08-12 | 416.21K shares derived: sum of 3 quarters · filed 2025-08-12 | 502.86K shares derived: sum of 4 quarters · filed 2025-08-12 |
| 2025-03-31 | 63.59K shares 10-Q · filed 2025-05-14 | 158.82K shares derived: sum of 2 quarters · filed 2025-05-14 | 245.47K shares derived: sum of 3 quarters · filed 2025-05-14 | 396.34K shares derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-12-31 | 95.24K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 181.88K shares derived: sum of 2 quarters · filed 2025-03-27 | 332.75K shares derived: sum of 3 quarters · filed 2025-03-27 | 610.08K shares 10-K · filed 2025-03-27 |
| 2024-09-30 | 86.64K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 237.51K shares derived: sum of 2 quarters · filed 2024-11-07 | 514.85K shares 10-Q · filed 2024-11-07 | |
| 2024-06-30 | 150.87K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | 428.20K shares 10-Q · filed 2024-08-06 | ||
| 2024-03-31 | 277.33K shares 10-Q · filed 2024-05-06 | |||
| 2023-12-31 | 1.67M shares 10-K · filed 2025-03-27 | |||
| 2022-12-31 | 1.36M shares 10-K · filed 2024-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |